माइटोटेन के इंटरैक्शन

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (आइवाब्राडिन लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (इरिनोटेकन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (उपाडासिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (उब्रोजेपेंट लेबल, दवाओं के इंटरैक्शन)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (एकालाब्रुटिनिब लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

• when coadministered with drugs that are strong inducers of CYP3A due to the potential for loss of therapeutic effect and development of resistance. (एटाज़ानाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (एपिक्साबैन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (एप्रेमिलास्ट लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (एबिराटेरोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) (एरिपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (एल्पेलिसिब लेबल, दवाओं के इंटरैक्शन)

Strongly induce CYP3A, which may lead to lower exposure of one or more components and loss of efficacy of GENVOYA and possible resistance. (एल्विटेग्राविर, कोबिसिस्टैट, एमट्रिसिटाबिन और टेनोफोविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. (ऑक्सीकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

If a CYP3A4 inducer is discontinued, consider OLINVYK dosage reduction and monitor for signs of respiratory depression. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Therefore, administration of potent enzyme inducers of CYP3A4 with ketoconazole tablets is not recommended. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (कैबोज़ैंटिनिब लेबल, दवाओं के इंटरैक्शन)

Intervention: Concomitant use of VRAYLAR with a CYP3A4 inducer is not recommended [see Dosage and Administration ( 2.1 , 2.6 ) ] . (कैरिप्राज़िन लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (कोडीन लेबल, बॉक्स्ड चेतावनी)

• Concomitant use of Strong CYP3A4 Inducers is not recommended. (क्लोज़ापिन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended. (ज़ोल्पिडेम लेबल, दवाओं के इंटरैक्शन)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (टिकाग्रेलोर लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin): Avoid use of HETLIOZ in combination with rifampin or other CYP3A4 inducers, because of decreased exposure ( 7.2 , 12.3 ) (टैसिमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (टोल्वैप्टन लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol are complex. (ट्रामाडोल और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Avoid concomitant use with strong CYP3A inducers if possible. (ट्रेटिनोइन लेबल, दवाओं के इंटरैक्शन)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (ट्रैबेक्टेडिन लेबल, दवाओं के इंटरैक्शन)

Co-administration of PREZCOBIX or PREZCOBIX PED with CYP3A inducers may lead to lower exposures of darunavir and cobicistat and potential loss of efficacy of darunavir and possible resistance. (डारुनाविर और कोबिसिस्टैट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (डासाटिनिब लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Moderate or Strong CYP3A4 inducers: Avoid concomitant use. (डैरिडोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (डॉक्सोरूबिसिन लेबल, दवाओं के इंटरैक्शन)

These drugs include, but are not limited to, the following: the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin the androgen receptor inhibitor enzalutamide the antimycobacterials rifampin, rifapentine the cytotoxic agent mitotane St. (डोराविरिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• CYP3A inducers: Avoid concomitant use. (ड्रोनेडेरोन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (थायोटेपा लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (नालोक्सेगोल लेबल, दवाओं के इंटरैक्शन)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (नाल्डेमेडिन लेबल, दवाओं के इंटरैक्शन)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (निफेडिपिन लेबल, दवाओं के इंटरैक्शन)

…contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (निर्माट्रेल्विर और रिटोनाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (निलोटिनिब लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

• CYP3A Inducers: Avoid concurrent use of IBRANCE with strong CYP3A inducers. (पाल्बोसिक्लिब लेबल, दवाओं के इंटरैक्शन)

Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of NUPLAZID. (पिमावैनसेरिन लेबल, दवाओं के इंटरैक्शन)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in meperidine plasma concentration. (पेथिडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (पैरासिटामोल और कोडीन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 and P-glycoprotein (P-gp) inducers : Avoid using a strong inducer of CYP3A4 and/or P-gp during a dosing interval for ERZOFRI. (पैलिपेरिडोन लेबल, दवाओं के इंटरैक्शन)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (प्राज़िक्वांटेल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex, requiring careful consideration of the effects on the parent drug, codeine, and the active metabolite, morphine. (प्रोमेथाज़िन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of fentanyl. (फेंटानिल लेबल, बॉक्स्ड चेतावनी)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (फ्लिबैनसेरिन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (बिक्टेग्राविर, एमट्रिसिटाबिन और टेनोफोविर एलाफेनामाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Strong CYP3A4 Inducers: Avoid concomitant use. (बोर्टेज़ोमिब लेबल, दवाओं के इंटरैक्शन)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (बोसुटिनिब लेबल, दवाओं के इंटरैक्शन)

The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Interactions with Drugs Affecting Cytochrome P450 Isoenzymes The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with codeine are complex. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, बॉक्स्ड चेतावनी)

Evaluate patients starting CYP3A4 inhibitors or stopping CYP3A4 inducers at frequent intervals for respiratory depression. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (मैसिटेंटन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Ella should not be administered with CYP3A4 inducers [see Drug interactions (7.1) and Clinical Pharmacology (12.3) ] . (यूलिप्रिस्टल लेबल, चेतावनियां और सावधानियां)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (रिटलेसिटिनिब लेबल, दवाओं के इंटरैक्शन)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (रिमेजेपेंट लेबल, दवाओं के इंटरैक्शन)

Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3) ] . (रिवारोक्साबैन लेबल, चेतावनियां और सावधानियां)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (रैनोलाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Drug Interactions: Use with strong cytochrome P450 enzyme inducers (e.g., rifampicin, phenobarbital, carbamazepine, phenytoin) is not recommended. (रोफ्लुमिलास्ट लेबल, चेतावनियां और सावधानियां)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (रोमिडेप्सिन लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (रोलापिटेंट लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (लुमाटेपेरोन लेबल, दवाओं के इंटरैक्शन)

Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1) ] . (लेनाकैपाविर लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Strong or moderate CYP3A inducers: Avoid concomitant use. (लेम्बोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Hormonal contraceptives: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Avoid strong CYP3A4 inducers. (लैपाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (लैरोट्रेक्टिनिब लेबल, दवाओं के इंटरैक्शन)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (लोरलाटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. (ल्यूरासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Warfarin: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (वाल्बेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (वेपडेजेस्ट्रेंट लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (सिरोलिमस लेबल, चेतावनियां और सावधानियां)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (सोराफेनिब लेबल, दवाओं के इंटरैक्शन)

Spironolactone: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

Spironolactone: Avoid concomitant use with LYSODREN. (माइटोटेन लेबल, दवाओं के इंटरैक्शन)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used Cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentrations. (हाइड्रोकोडोन और पैरासिटामोल लेबल, बॉक्स्ड चेतावनी)

In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, बॉक्स्ड चेतावनी)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (माइटोटेन लेबल, बॉक्स्ड चेतावनी)

• Use with CYP3A Inducers: Increase the risk of reduced efficacy of alprazolam. (अल्प्राज़ोलम लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (आइफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

Concomitant Use with CYP3A Inducers Use of KALYDECO with strong CYP3A inducers, such as rifampin, substantially decreases the exposure of ivacaftor, which may reduce the therapeutic effectiveness of KALYDECO. (आइवाकैफ्टर लेबल, चेतावनियां और सावधानियां)

The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary. (इमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers may decrease Gleevec C max and area under curve (AUC). (इमैटिनिब लेबल, दवाओं के इंटरैक्शन)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (एक्सिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (एक्सेमेस्टेन लेबल, दवाओं के इंटरैक्शन)

Prolonged Bleeding Time LYSODREN can cause platelet function disorders due to abnormal adenosine diphosphate (ADP)-induced platelet aggregation. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (एम्लोडिपिन और एटोरवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (एम्लोडिपिन और ओल्मेसार्टन लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (एम्लोडिपिन और बेनाज़ेप्रिल लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (एम्लोडिपिन और वाल्सार्टन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers Pre-treatment with a CYP3A4 inducer prior to erlotinib decreased erlotinib exposure [see Clinical Pharmacology (12.3) ]. (एर्लोटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducer and P-gp inducer : Increase the dosage as recommended. (एवरोलिमस लेबल, दवाओं के इंटरैक्शन)

Table 4: Clinically Relevant Interactions Affecting Esomeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4. (एस्ज़ोपिक्लोन लेबल, दवाओं के इंटरैक्शन)

While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations. (एस्टाज़ोलम लेबल, चेतावनियां)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (ओन्डैनसेट्रॉन लेबल, दवाओं के इंटरैक्शन)

Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Table 6: Clinically Relevant Interactions Affecting Omeprazole when Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, दवाओं के इंटरैक्शन)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (ओल्मेसार्टन, एम्लोडिपिन और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (कैनाग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

• Strong inducer of CYP3A4 or CYP2C19: Consider dose increase of EPIDIOLEX. (कैनाबिडियोल (प्रिस्क्रिप्शन दवा) लेबल, दवाओं के इंटरैक्शन)

Inducers of Hepatic CYP Enzymes Rifampin : Rifampin is a potent CYP3A4 inducer and concomitant administration with caspofungin acetate for injection is expected to reduce the plasma concentrations of caspofungin acetate for injection. (कैस्पोफंगिन लेबल, दवाओं के इंटरैक्शन)

Due to increased steroid clearance and increase of steroid-binding protein, high-dose replacement therapy may be required and free cortisol and corticotropin (ACTH) should be monitored to adapt the systemic corticosteroids. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (क्लिंडामाइसिन लेबल, दवाओं के इंटरैक्शन)

Miscellaneous Cytochrome P450 Inducers: Efavirenz Nevirapine Rifampicin Rifabutin Rifapentine Use With Caution Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. (क्लैरिथ्रोमाइसिन लेबल, दवाओं के इंटरैक्शन)

…several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. (क्लोमिप्रामिन लेबल, दवाओं के इंटरैक्शन)

Antiepileptics (AEDs) (Carbamazepine, Phenobarbital, and Phenytoin) Carbamazepine, phenobarbital, and phenytoin are CYP3A4 inducers and may decrease quinine plasma concentrations if used concurrently with quinine sulfate. (क्विनीन लेबल, दवाओं के इंटरैक्शन)

• Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7-14 days) of potent CYP3A4 inducers (e.g., phenytoin, rifampin, St. (क्वेटियापिन लेबल, दवाओं के इंटरैक्शन)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (ग्वानफेसिन लेबल, दवाओं के इंटरैक्शन)

Pharmacokinetic Interactions Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. (ज़िप्रासिडोन लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (जेफिटिनिब लेबल, दवाओं के इंटरैक्शन)

Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon C max and AUC by approximately 80%. (ज़ेलेप्लॉन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers If co-administration with a potent CYP3A4 inducer is necessary, the patient should be closely monitored and the dose of ZONISAMIDE and other drugs that CYP3A4 substrates may need to be adjusted [see Clinical Pharmacology ( 12.3 )] . (ज़ोनिसामाइड लेबल, दवाओं के इंटरैक्शन)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers/inhibitors: Monitor for decreased tinidazole effect or increased adverse reactions ( 7.2 ) (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Use of tiagabine HCl without enzyme-inducing antiepileptic drugs results in blood levels about twice those attained in the studies on which current dosing recommendations are based (see DOSAGE AND ADMINISTRATION ). (टियागाबिन लेबल, चेतावनियां)

Co-administration with Inducers or Inhibitors of CYP3A Metabolism Agents Inducing CYP3A Metabolism: Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. (टेम्सिरोलिमस लेबल, चेतावनियां और सावधानियां)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (टेल्मिसार्टन और एम्लोडिपिन लेबल, दवाओं के इंटरैक्शन)

Risk of Rejection with Strong CYP3A Inducers and Risk of Serious Adverse Reactions with Strong CYP3A Inhibitors The concomitant use of strong CYP3A inducers may increase the metabolism of tacrolimus, leading to lower whole blood trough concentrations and greater risk of rejection. (टैक्रोलिमस लेबल, चेतावनियां और सावधानियां)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (टैडालाफिल लेबल, दवाओं के इंटरैक्शन)

…exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ… (टोफासिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong Inducers of CYP 3A Clinical implication Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. (ट्रायज़ोलम लेबल, दवाओं के इंटरैक्शन)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (ट्रेप्रोस्टिनिल लेबल, चेतावनियां और सावधानियां)

CYP3A4 Inducers: Increase in RALDESY dosage may be necessary ( 2.5 , 7 ). (ट्रैज़ोडोन लेबल, दवाओं के इंटरैक्शन)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (डाइवैल्प्रोएक्स (वैल्प्रोएट) लेबल, दवाओं के इंटरैक्शन)

Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of PREZISTA/ritonavir, respectively. (डारुनाविर लेबल, चेतावनियां और सावधानियां)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (डेक्सलैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (डॉक्सरकैल्सिफेरॉल लेबल, दवाओं के इंटरैक्शन)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (डोफेटिलाइड लेबल, दवाओं के इंटरैक्शन)

DRUG INTERACTIONS Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene. (थायोथिक्सीन लेबल, दवाओं के इंटरैक्शन)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (निंटेडानिब लेबल, दवाओं के इंटरैक्शन)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (निमोडिपिन लेबल, चेतावनियां और सावधानियां)

Table 4: Clinically Significant Interactions with Esomeprazole Magnesium - Affecting Co-Administered Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact : Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (नेप्रोक्सेन और एसोमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (पिटोलिसेंट लेबल, दवाओं के इंटरैक्शन)

Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. (पेरैम्पेनल लेबल, दवाओं के इंटरैक्शन)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (फेनोप्रोफेन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers No dosing adjustments are recommended in the presence of CYP3A4 inducers, such as rifampin and carbamazepine. (फेसोटेरोडिन लेबल, दवाओं के इंटरैक्शन)

Initiation of medications that inhibit or induce CYP3A may increase or decrease concentrations of fosamprenavir calcium/ritonavir, respectively. (फोसएम्प्रेनाविर लेबल, चेतावनियां और सावधानियां)

CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ and concomitant drugs. (फोसाप्रेपिटेंट लेबल, चेतावनियां और सावधानियां)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (फ्लेकेनाइड लेबल, दवाओं के इंटरैक्शन)

Other inhibitors and inducers of CYP3A4: Substances that inhibit CYP3A4, such as ketoconazole or ritonavir, may inhibit buspirone metabolism and increase plasma concentrations of buspirone while substances that induce CYP3A4, such as dexamethasone or certain anticonvulsants (phenytoin, phenobarbital, carbamazepine), may increase the rate of buspirone metabolism. (बस्पिरोन लेबल, दवाओं के इंटरैक्शन)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (बेक्साग्लिफ्लोज़िन लेबल, दवाओं के इंटरैक्शन)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3) ] , potentially resulting in decreased efficacy… (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 inducers Double the recommended dosage and further adjust based on clinical response. (ब्रेक्सपिप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (ब्रोमोक्रिप्टिन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (मिथाइलएर्गोमेट्रिन लेबल, दवाओं के इंटरैक्शन)

John's Wort, tramadol, tryptophan, buspirone Strong CYP3A Inducers Clinical Impact The concomitant use of strong CYP3A inducers with REMERON/REMERONSolTab decreases the plasma concentration of mirtazapine [see Clinical Pharmacology (12.3) ] . (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

…agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), fluconazole, fluvoxamine, some selective serotonin reuptake inhibitors (SSRIs) (e.g., sertraline, fluvoxamine) Inducers of CYP3A4, CYP2B6, CYP2C19, or CYP2C9 Clinical Impact: The concomitant use of methadone and CYP3A4, CYP2B6, CYP2C19, or CYP2C9 inducers can decrease the plasma concentration… (मेथाडोन लेबल, दवाओं के इंटरैक्शन)

Rifampin (Potent Inducer of CYP3A4) Coadministration of a single 500 mg oral dose of mefloquine and 600 mg of rifampin once daily for 7 days in 7 healthy Thai volunteers resulted in a decrease in the mean C max and AUC of mefloquine by 19% and 68%, respectively, and a decrease in the mean elimination half-life of mefloquine from 305 hours to 113 hours. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (मैराविरोक लेबल, चेतावनियां और सावधानियां)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (रक्सोलिटिनिब लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. (रिफाब्यूटिन लेबल, दवाओं के इंटरैक्शन)

Coadministration of EDURANT or EDURANT PED and drugs that induce CYP3A may result in decreased plasma concentrations of rilpivirine and loss of virologic response and possible resistance to rilpivirine or to the class of NNRTIs. (रिल्पिविरिन लेबल, दवाओं के इंटरैक्शन)

Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. (रिस्पेरिडोन लेबल, दवाओं के इंटरैक्शन)

Effects of Other AEDs on BANZEL Potent cytochrome P450 enzyme inducers, such as carbamazepine, phenytoin, primidone, and phenobarbital, appear to increase the clearance of BANZEL (see Table 6). (रुफिनामाइड लेबल, दवाओं के इंटरैक्शन)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (रेपाग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

Rifampin (strong CYP enzyme inducer): Decreases exposure to and effects of ramelteon. (रैमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (लिनाग्लिप्टिन लेबल, दवाओं के इंटरैक्शन)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (लिनाग्लिप्टिन और मेटफॉर्मिन लेबल, दवाओं के इंटरैक्शन)

Table 2: Drugs That May Alter Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (लियोथायरोनिन लेबल, दवाओं के इंटरैक्शन)

…Drugs That May Alter T 4 and Triiodothyronine (T 3 ) Serum Transport Without Effecting Free Thyroxine (FT 4 ) Concentration (Euthyroidism) Drug or Drug Class Effect Clofibrate Estrogen-containing oral contraceptives Estrogens (oral) Heroin/Methadone 5-Fluorouracil Mitotane Tamoxifen These drugs may increase serum thyroxine-binding globulin (TBG) concentration. (लेवोथायरोक्सिन लेबल, दवाओं के इंटरैक्शन)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (लैंसोप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

…Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↓ lopinavir ↑ glucocorticoids Coadministration with oral dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to lopinavir. (लोपिनाविर और रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

CYP3A4 Inducers: Consider increasing VIIBRYD dosage by 2-fold, up to 80 mg once-daily over 1 to 2 weeks when used concomitantly with strong CYP3A4 inducers for greater than 14 days ( 2.4 , 7 ). (विलाज़ोडोन लेबल, दवाओं के इंटरैक्शन)

CYP3A4 inducers decrease verapamil levels ( 7.1 ) (वेरापामिल लेबल, दवाओं के इंटरैक्शन)

Hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, rifampin) can increase valproate clearance, while enzyme inhibitors (e.g., felbamate) can decrease valproate clearance. (वैल्प्रोइक एसिड लेबल, दवाओं के इंटरैक्शन)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducers: Efficacy may be reduced ( 7.2 ). (सुवोरेक्सेंट लेबल, दवाओं के इंटरैक्शन)

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution. (सेलेजिलिन लेबल, दवाओं के इंटरैक्शन)

Drugs that May Decrease Haloperidol Plasma Concentrations Coadministration of haloperidol with potent enzyme inducers of CYP3A4 may gradually decrease the plasma concentrations of haloperidol to such an extent that efficacy may be reduced. (हेलोपेरिडोल लेबल, दवाओं के इंटरैक्शन)

Potential for Etravirine to Affect Other Drugs Etravirine is an inducer of CYP3A and inhibitor of CYP2C9, CYP2C19 and P-glycoprotein (P-gp). (एट्राविरिन लेबल, दवाओं के इंटरैक्शन)

TAF is not an inhibitor or inducer of CYP3A in vivo . (एमट्रिसिटाबिन और टेनोफोविर लेबल, दवाओं के इंटरैक्शन)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (एरिबुलिन लेबल, दवाओं के इंटरैक्शन)

The selective serotonin reuptake inhibitors sertraline (weak CYP3A4 inducer) and fluoxetine (CYP2D6 inhibitor), and the anti-epileptic drug felbamate (CYP2C19 inhibitor and CYP3A4 inducer) do not affect the pharmacokinetics of clonazepam. (क्लोनाज़ेपाम लेबल, दवाओं के इंटरैक्शन)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (ग्लिसरॉल फिनाइलब्यूटिरेट लेबल, दवाओं के इंटरैक्शन)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur. (डाइसोपाइरामाइड लेबल, दवाओं के इंटरैक्शन)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (डोसेटैक्सेल लेबल, दवाओं के इंटरैक्शन)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (मेक्सिलेटिन लेबल, दवाओं के इंटरैक्शन)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (रिफैक्सिमिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (रियोसिगुआट लेबल, दवाओं के इंटरैक्शन)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (माइटोटेन लेबल, चेतावनियां और सावधानियां)

Concurrent use of strong CYP3A inducers (e.g., St. (विन्क्रिस्टिन लेबल, दवाओं के इंटरैक्शन)

Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin). (एसेनापिन लेबल, दवाओं के इंटरैक्शन)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (माइकाफंगिन लेबल, दवाओं के इंटरैक्शन)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (मोंटेलुकास्ट लेबल, दवाओं के इंटरैक्शन)